Хайлтын үр дүнгүүд - Alejandro D. Ricart

  • 8-н 1 - 8 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Drug-induced liver injury in Oncology

    Drug-induced liver injury in Oncology -н Alejandro D. Ricart

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar<scp>PF</scp>‐05280014 with trastuzumab in healthy volunteers (<scp>REFLECTIONS B</scp>327‐01)

    A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar<scp>PF</scp>‐05280014 with trastuzumab in healthy volunteers (<scp>REFLECTIONS B</scp>327‐01) -н Donghua Yin, Kerry Barker, Ruifeng Li, Meng Xu, Steven D. Reich, Alejandro D. Ricart, Dan Rudin, Carrie Turich Taylor, Charles Zacharchuk, Arne G. Hansson

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study -н Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding

    Хэвлэсэн 2008
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure -н Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Jean‐Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen Snyder, Alejandro D. Ricart, Arun Balakumaran, Shelonitda Rose, Craig H. Moskowitz

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

    Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors -н Brian I. Rini, Joan H. Schiller, John P. Fruehauf, Ezra E.W. Cohen, Jamal Tarazi, Brad Rosbrook, Angel H. Bair, Alejandro D. Ricart, Anthony J. Olszanski, Kristen J. Letrent, Sinil Kim, Olivier Rixe

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

    Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advance... -н Monica Mita, Alain C. Mita, Quincy Chu, Eric K. Rowinsky, Gerald J. Fetterly, M. Goldston, Amita Patnaik, Lesley Mathews, Alejandro D. Ricart, Theresa A. Mays, Heather Knowles, Victor M. Rivera, Jeff Kreisberg, Camille L. Bedrosian, Anthony W. Tolcher

    Хэвлэсэн 2008
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma -н Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Craig H. Moskowitz

    Хэвлэсэн 2017
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

    Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study -н Craig H. Moskowitz, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Eric L. Gustafson, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Robert W. Chen

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: